Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease

Study:

A Phase 2 Dose-Finding Clinical Trial of CARDIOsphere® (PB127) in Normal Volunteers and in Patients With Known or Suspected Coronary Artery Disease

Rationale:

n/a

Purpose:

The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Healthy
Coronary Artery Disease
Drug: PB127 for Injectable Suspension Phase 2

Verified by Point Biomedical April, 2008

Sponsored by: Point Biomedical
Information provided by: Point Biomedical
ClinicalTrials.gov identifier: NCT00584818

Study Type: Interventional

Study Design: Diagnostic, Open Label, Single Group Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Alexander Ehlgen, MD, PhD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site